Biolegend, 353208, Brilliant Violet 421™ anti-human CD197 (CCR7) Antibody, 100tests

CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: CCR7-transfected cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Product Citations: Ols S, et al. 2020. Cell Reports. 30(12):3964-3971. PubMed Im KW, et al. 2023. NPJ Breast Cancer. 9:22. PubMed Preglej T, et al. 2023. Front Immunol. 14:1096096. PubMed Yan F, et al. 2023. Front Cell Infect Microbiol. 13:1152987. PubMed Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed Combes AJ, et al. 2022. Cell. 185:184. PubMed Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed Zhong J, et al. 2023. Front Immunol. 13:1081889. PubMed Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed Cassotta A, et al. 2019. Nat Med. 25:1402. PubMed Spandan V Shah et al. 2018. Cell reports. 25(10):2766-2774 . PubMed Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed Ramaswamy A, et al. 2021. Immunity. 54(5):1083-1095.e7. PubMed Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed Wallin J, et al. 2016. Nat Commun. 7:12624. PubMed Geiger R, et al. 2016. Cell. 167:829-842. PubMed van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed Azeem W, et al. 2021. Biomedicines. 9: . PubMed Yu C, et al. 2021. Med (N Y). 2:755. PubMed Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed Bziat V, et al. 2021. Cell. . PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed Marcandalli J et al. 2019. Cell. 176(6):1420-1431 . PubMed Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed Omer B, et al. 2022. Cancer Immunol Res. 10:512. PubMed Neumann B, et al. 2015. J Leukoc Biol. 97:19. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed Azeem W, et al. 2020. Front Immunol. 11:438. PubMed Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed Nobs SP, et al. 2017. J Exp Med. 214:3015. PubMed Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed Gustafson CE, et al. 2020. JCI Insight. 5:. PubMed Benner M, et al. 2020. Cell Rep. 32:108204. PubMed Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed Fu J, et al. 2021. J Clin Invest. 131:. PubMed Grutza R, et al. 2020. J Immunol. 204:2910. PubMed Cassotta A, et al. 2020. Eur J Immunol. . PubMed Gerna G, et al. 2015. J Gen Virol. 96:360. PubMed Vadaq N, et al. 2022. iScience. 25:105089. PubMed
RRID: AB_10915137 (BioLegend Cat. No. 353207) AB_11203894 (BioLegend Cat. No. 353208)
Structure: Chemokine receptor, G protein-coupled receptors (GPCR), seven transmembrane receptor.
Distribution: T cells, B cells, NK, dendritic cells.
Function: The chemokine receptor CCR7 plays a pivotal role in the homing of naïve T cells and regulatory T cells to secondary lymphoid organs, and the migration of dendritic cells into afferent lymphatic vessels.
Ligand/Receptor: CCL19 and CCL21.
Cell Type: B cells, Dendritic cells, NK cells, T cells
Biology Area: Immunology
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors, GPCR
Antigen References: 1. Yanagihara S, et al. 1998. J. Immunol. 161:3096. 2. Charo IF, et al. 2006. N. Engl. J. Med. 354:610. 3. Reif K, et al. 2002. Nature 416:94. 4. Nakata B, et al. 2008. Oncology 74:69. 5. Brodie T. et al. 2013. Cytometry A. 6: 530-2. PubMed 6. Graves A.J. et al. 2014. Cytometry A. 7: 576–9 PubMed 7. Moncunill G. et al. 2014. Cytometry A. 12: 995-8 PubMed
Gene ID: 1236
UniProt: View information about CD197 on UniProt.org
Clone: G043H7
Regulatory Status: RUO
Other Names: BLR2, CDw197, EBI1, CMKBR7
Isotype: Mouse IgG2a, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.
Q: Does staining at room temperature or even at 37°C help for checking chemokine receptors expression?
A: Due to continuous recycling of many chemokine receptors, it may be worthwhile to consider staining at room temperature or at 37°C if the staining at lower temperature (which can potentially reduce receptor turnover) is not optimal.